昊海生科(688366.SH)业绩快报:2025年归母净利润2.51亿元,同比减少40.30%
Ge Long Hui A P P·2026-02-27 11:45

Group 1 - The company reported a revenue of 2.473 billion yuan for the fiscal year 2025, representing a year-on-year decrease of 8.33% [1] - The net profit attributable to the parent company was 251 million yuan, down 40.30% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 160 million yuan, a decrease of 57.67% year-on-year [1] Group 2 - The company's subsidiary, Shenzhen New Industry Ophthalmic New Technology Co., faced significant operational pressure due to the second phase of the national volume-based procurement for artificial lenses and intensified industry competition [2] - The total number of cataract surgeries in China in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - The increase in domestic competitors, particularly those offering significant cost advantages, has negatively impacted the sales price and volume of the imported Lenstec brand products [2] - The company anticipates a decrease in sales profit for Shenzhen New Industry in 2025 and has prudently recognized an impairment provision of approximately 140 million yuan for goodwill [2]

HAOHAI BIOTEC-昊海生科(688366.SH)业绩快报:2025年归母净利润2.51亿元,同比减少40.30% - Reportify